Document Detail

Hormone response in ovarian cancer: time to reconsider as a clinical target?
MedLine Citation:
PMID:  23045324     Owner:  NLM     Status:  MEDLINE    
Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response.
Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Related Documents :
11129754 - Returning to the bedside: using the history and physical examination to identify rotato...
23119744 - Spectrum of head-neck cancers at allahabad.
23551194 - Molecular testing guideline for selection of lung cancer patients for egfr and alk tyro...
24220554 - Follow-up care, surveillance protocol, and secondary prevention measures for survivors ...
18559494 - Cisplatin induces p53-dependent flice-like inhibitory protein ubiquitination in ovarian...
15302504 - Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-09
Journal Detail:
Title:  Endocrine-related cancer     Volume:  19     ISSN:  1479-6821     ISO Abbreviation:  Endocr. Relat. Cancer     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-12-31     Revised Date:  2014-04-21    
Medline Journal Info:
Nlm Unique ID:  9436481     Medline TA:  Endocr Relat Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  R255-79     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / therapeutic use
Hormones / metabolism*
Neoplasms, Glandular and Epithelial / drug therapy,  epidemiology,  metabolism*
Ovarian Neoplasms / drug therapy,  epidemiology,  metabolism*
Receptors, Cell Surface / metabolism
Grant Support
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Hormones; 0/Receptors, Cell Surface

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  [Experience with cardiac magnetic resonance imaging in patient management at the Markusovszky Hospit...
Next Document:  Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas.